The Li Ka Shing Foundation has announced a new charitable medical initiative that will provide Histotripsy treatment for 200 eligible liver cancer patients in Hong Kong over a three-year period. The programme forms part of the foundation’s broader “Love Can Help” healthcare support initiative aimed at improving access to advanced medical technologies.
Histotripsy is a non-invasive ultrasound-based treatment technology that uses focused sound waves to destroy tumors without the need for traditional surgery. The treatment is gaining attention globally for its potential to reduce recovery times and minimize damage to surrounding tissues compared to conventional cancer procedures.
The initiative is being implemented in collaboration with three Hong Kong medical institutions: the Chinese University of Hong Kong Medical Centre, Gleneagles Hospital Hong Kong, and Hong Kong Sanatorium & Hospital. Through the programme, eligible patients will be able to access Histotripsy treatment at a significantly reduced cost of HKD50,000 with support from participating hospitals and the foundation.
The funding programme reflects growing interest in expanding access to next-generation cancer treatment technologies across Asia. By subsidizing advanced therapies that may otherwise remain inaccessible to many patients, the initiative aims to improve treatment affordability and encourage wider adoption of innovative non-invasive medical solutions.
